No Data
Truist Securities Maintains Buy on Arcellx, Maintains $87 Price Target
Truist Securities analyst Asthika Goonewardene maintains Arcellx with a Buy and maintains $87 price target.
Truist Financial Maintains Arcellx(ACLX.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Arcellx(ACLX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 31.7% and a total average return of -4.5% ove
Arcellx(ACLX.US) Officer Sells US$1.1 Million in Common Stock
$Arcellx(ACLX.US)$ Officer Heery Christopher sold 20,000 shares of common stock on Jun 12, 2024 at an average price of $55.1334 for a total value of $1.1 million.Source: Announcement What is statement
Arcellx Insider Sold Shares Worth $1,102,668, According to a Recent SEC Filing
Christopher Heery, Chief Medical Officer, on June 12, 2024, sold 20,000 shares in Arcellx (ACLX) for $1,102,668. Following the Form 4 filing with the SEC, Heery has control over a total of 9,278 share
Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns
Growth Investors: Industry Analysts Just Upgraded Their Arcellx, Inc. (NASDAQ:ACLX) Revenue Forecasts By 14%
Arcellx, Inc. (NASDAQ:ACLX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The revenue forecast for this year has e